Smith & Nephew SNATS (NYSE:SNN) Lowered to Buy Rating by Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

A number of other research firms also recently weighed in on SNN. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Canaccord Genuity Group cut their target price on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. Finally, Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Smith & Nephew SNATS has a consensus rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Trading Up 1.2%

Shares of Smith & Nephew SNATS stock opened at $36.10 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The firm has a 50 day simple moving average of $33.77 and a 200 day simple moving average of $34.94. Smith & Nephew SNATS has a fifty-two week low of $23.91 and a fifty-two week high of $38.79.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SNN. Bank of Montreal Can grew its holdings in Smith & Nephew SNATS by 321.6% during the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after purchasing an additional 2,616,301 shares during the period. River Road Asset Management LLC grew its holdings in shares of Smith & Nephew SNATS by 9.3% in the 2nd quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock valued at $97,175,000 after buying an additional 270,480 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Smith & Nephew SNATS by 5.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock valued at $67,383,000 after buying an additional 100,697 shares in the last quarter. Brandes Investment Partners LP raised its stake in Smith & Nephew SNATS by 4.1% during the 2nd quarter. Brandes Investment Partners LP now owns 1,604,400 shares of the medical equipment provider’s stock worth $49,143,000 after buying an additional 63,778 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Smith & Nephew SNATS by 6,663.4% during the second quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after acquiring an additional 1,192,755 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.